Shield Therapeutics (LSE:STX) reported a significant improvement in first-quarter 2026 results, with group net revenues reaching $18 million and EBIT moving into positive territory at approximately $2.5 million. Performance was driven by a $7.9 million milestone payment from its Chinese partner ASK Pharm and a 54% year-on-year increase in U.S. ACCRUFeR sales to $9.9 million. The company cited strong prescription growth, modest pricing gains, and tighter cost and working capital management, which helped lift cash balances to $12.4 million. However, it noted that new prior authorisation requirements under New York Medicaid could impact sales as the business shifts more toward commercially insured patients.
Regulatory Progress and Leadership Change
Momentum on the regulatory front continued, with National Medical Products Administration accepting a marketing application for ACCRUFeR in China. In Europe, European Medicines Agency expanded the label for FeRACCRU to include children aged over 12, broadening its potential patient base. Alongside these developments, the company announced that CFO Santosh Shanbhag will step down on 1 June 2026. CEO Anders Lundstrom will assume the role on an interim basis while a permanent replacement is sought, as the company also increases investor engagement through a new digital hub and webinar programme.
Financial Outlook and Key Considerations
Despite the return to profitability in the quarter, Shield’s broader outlook remains constrained by weak financial quality indicators, including ongoing losses over longer periods, negative operating and free cash flow, and negative equity. These challenges are partly offset by improving revenues, strengthening margins, and moderately positive price trends. Valuation remains difficult to support given its loss-making status and lack of dividend yield.
More about Shield Therapeutics
Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on treating iron deficiency and iron deficiency anaemia. Its lead product, ferric maltol, is marketed as ACCRUFeR in the United States and FeRACCRU in other markets. The company is targeting a large global patient population through its own U.S. commercial operations and a network of regional licensing partners across Europe, Asia-Pacific, and North America.
Leave a Reply